Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate
Portfolio Pulse from Vandana Singh
Blue Water Biotech Inc (NASDAQ:BWV) has released encouraging preclinical data for its monkeypox vaccine candidate, developed using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform. The vaccine candidate has shown potential in neutralizing the vaccinia virus, which is closely related to monkeypox. Meanwhile, Roche Holdings AG's (OTC:RHHBY) cobas MPXV has received FDA Emergency Use Authorization for detecting monkeypox DNA.
June 28, 2023 | 5:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Blue Water Biotech's preclinical data for its monkeypox vaccine candidate is encouraging, potentially leading to a new product in the market.
The positive preclinical data for Blue Water Biotech's monkeypox vaccine candidate could lead to further development and eventual market entry, potentially boosting the company's revenues and stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roche Holdings AG's cobas MPXV has received FDA Emergency Use Authorization for detecting monkeypox DNA, expanding its product offerings.
The FDA's Emergency Use Authorization for Roche's cobas MPXV for monkeypox detection expands the company's product offerings, potentially increasing its revenues and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50